<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656563</url>
  </required_header>
  <id_info>
    <org_study_id>CURC-004</org_study_id>
    <secondary_id>17848</secondary_id>
    <nct_id>NCT02656563</nct_id>
  </id_info>
  <brief_title>Radium 223 Following Intermittent ADT</brief_title>
  <acronym>RAND</acronym>
  <official_title>Phase II, Randomized, Open Label to Evaluate Efficacy,Safety of Radium 223 in Prolonging the Off Treatment Interval in Men With Rising PSA Post-rad, or Post-prostatectomy Without Bone Mets on Intermittent Androgen Ablation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Urology Research Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Urology Research Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, phase II, randomized, open label study to evaluate the efficacy and&#xD;
      safety of monthly Radium 223 in prolonging the off treatment interval of men with localized&#xD;
      prostate cancer receiving intermittent androgen ablation therapy for a rising PSA&#xD;
      post-radiation or post-prostatectomy, who are at high risk for occult metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will be randomized in a 1:1 ratio to receive either (1) study medication,&#xD;
      Radium 223 monthly for six months or (2) no treatment (usual care). All patients will have a&#xD;
      physical exam, PSA, testosterone and clinical lab tests conducted monthly. Group 1 will&#xD;
      receive monthly Radium 233 beginning one month after discontinuing ADT, for a maximum of 6&#xD;
      months of treatment. Radium-223 will be given in accordance with the Canadian product label&#xD;
      and Product Monograph at 50kBq/kg.&#xD;
&#xD;
      If PSA reaches 5ng/ml before 7 months after discontinuing ADT, the patient will discontinue&#xD;
      Radium 223 and resume ADT. Group 2 will have no further therapy until their PSA reaches&#xD;
      5ng/ml, at which point they will resume ADT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA &gt; 5.0ng/ml</measure>
    <time_frame>Time to PSA &gt; 5.0ng/ml in the off treatment, through study completion at 2 years.</time_frame>
    <description>Time to PSA &gt; 5.0ng/ml in the off treatment interval during intermittent androgen ablation therapy, as measured from randomization.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Radium 223 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radium 223 Dichloride (Xofigo®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Treatment Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control Arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radium 223 Dichloride (Xofigo®)</intervention_name>
    <description>Radium 223 Dichloride (Xofigo®) monthly for six months</description>
    <arm_group_label>Radium 223 Arm</arm_group_label>
    <other_name>Xofigo®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to read and write (health outcome questionnaires are self- administered),&#xD;
             understand instructions related to study procedures and to give written informed&#xD;
             consent.&#xD;
&#xD;
          2. Age ≥ 45 and ≤ 85 years.&#xD;
&#xD;
          3. Histologically documented diagnosis (including Gleason grade) of adenocarcinoma of the&#xD;
             prostate.&#xD;
&#xD;
          4. Subject has received external beam radiation, brachytherapy or radical prostatectomy&#xD;
             for the treatment of localized prostate cancer, or is being treated with primary&#xD;
             androgen deprivation.&#xD;
&#xD;
          5. Subject has completed intermittent androgen ablation therapy or is about to complete&#xD;
             ADT.&#xD;
&#xD;
          6. Patients treated with brachytherapy must be at least 3 years post implant.&#xD;
&#xD;
          7. Subject meets both of the following criteria:&#xD;
&#xD;
               -  PSA &gt;5.0 and &lt; 100 ng/ml and rising on 2 successive occasions at least one month&#xD;
                  apart prior to ADT. PSA must be &lt; 2.0 after 6-8 months of ADT (+/- 4 weeks). At&#xD;
                  month 8 (or within 4 weeks after month 8), following documentation that PSA &lt;2.0,&#xD;
                  patients will be entered.&#xD;
&#xD;
               -  Patients must also have two of the following high risk criteria:&#xD;
&#xD;
                    -  Primary Gleason score &gt;8&#xD;
&#xD;
                    -  Baseline PSA &gt; 20 ng/ml (pre-treatment)&#xD;
&#xD;
                    -  PSA recurrence &gt; 0.2 within 1 year (post RP)&#xD;
&#xD;
                    -  PSA DT prior to ADT &lt; 6 months&#xD;
&#xD;
                    -  PSA &gt; 1.0 ng/ml after 8 months of ADT&#xD;
&#xD;
          8. Adequate hematological, liver, and renal function including:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 x109/L&#xD;
&#xD;
               -  Platelet count ≥ 100 x109/L&#xD;
&#xD;
               -  Hemoglobin ≥10.0 g/dL (100 g/L; 6.2 mmol/L)&#xD;
&#xD;
               -  Total bilirubin level ≤ 1.5 x institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN&#xD;
&#xD;
               -  Albumin &gt; 25 g/L&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group Performance (ECOG) performance 0 or 1 (Appendix 2).&#xD;
&#xD;
         10. Negative bone scan and negative CT scan for visceral (extra nodal) mets within 12&#xD;
             months of study entry. Bone scan and CT may be performed after initiation of ADT. If&#xD;
             lymphadenopathy present, must be &lt;3 cm in shortest diameter.&#xD;
&#xD;
         11. Able to swallow and retain oral medication.&#xD;
&#xD;
         12. Able and willing to participate in the full study.&#xD;
&#xD;
         13. Willingness to use condoms if sexually active.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment for prostate cancer with any of the following:&#xD;
&#xD;
               -  Chemotherapy&#xD;
&#xD;
               -  Hormonal therapy (e.g. megestrol, medroxyprogesterone, cyproterone, DES) within&#xD;
                  the previous year. (Note: Patients who are on their first cycle of intermittent&#xD;
                  androgen deprivation therapy within 8 months of initiating treatment are&#xD;
                  eligible).&#xD;
&#xD;
               -  Glucocorticoids (except inhaled or topical) within the previous 3 months.&#xD;
&#xD;
               -  Ketoconazole&#xD;
&#xD;
          2. Concurrent and previous use within 3 months of the following medications:&#xD;
&#xD;
               -  Finasteride&#xD;
&#xD;
               -  Dutasteride&#xD;
&#xD;
               -  Any investigational 5α-reductase inhibitors&#xD;
&#xD;
               -  Anabolic steroids&#xD;
&#xD;
               -  Medications with anti-androgenic properties such as cimetidine.&#xD;
&#xD;
          3. Patients may not be receiving any other investigational agents within 30 days prior to&#xD;
             the first dose of study drug or anytime during the study period.&#xD;
&#xD;
          4. Subject currently has evidence of distant metastases on bone scan, or visceral&#xD;
             metastases on CT scan. Patients with bulky LN mets. (&gt; 3 cm in shortest diameter).&#xD;
             (Note: Adenopathy &lt; 3 cm in shortest diameter is not an exclusion criterion).&#xD;
&#xD;
          5. Subject has received adjuvant or neoadjuvant androgen ablation within the previous 12&#xD;
             months.&#xD;
&#xD;
          6. Any unstable serious co-existing medical condition(s) including but not limited to&#xD;
             uncontrolled diabetes, peptic ulcer disease, Crohn's disease and ulcerative colitis.&#xD;
&#xD;
          7. Abnormal liver function tests (alkaline phosphatase [ALP], alanine aminotransferase&#xD;
             [ALT], aspartate aminotransferase [AST]) &gt; 2.5 times upper limit of normal (ULN) or&#xD;
             bilirubin &gt; 1.5 times ULN)&#xD;
&#xD;
          8. Previous malignancy (not including curatively treated basal or squamous cell carcinoma&#xD;
             of the skin within the previous 2 years or Ta bladder cancer with negative&#xD;
             surveillance cystoscopy within the past year).&#xD;
&#xD;
          9. History or current evidence of drug or alcohol abuse within the past 12 months.&#xD;
&#xD;
         10. History of any illness that, in the opinion of the investigator, might confound the&#xD;
             results of the study or pose additional risk to the subject. This includes:&#xD;
&#xD;
               -  Imminent spinal cord compression based on clinical findings and/or magnetic&#xD;
                  resonance imaging (MRI). Patients with history of spinal cord compression should&#xD;
                  have completely recovered.&#xD;
&#xD;
               -  Any infection ≥ National Cancer Institute Common Terminology Criteria for Adverse&#xD;
                  Events (NCI-CTCAE) version 4.03 Grade 2&#xD;
&#xD;
               -  Cardiac Failure New York Heart Association (NYHA) Class III or IV&#xD;
&#xD;
               -  Bone marrow dysplasia&#xD;
&#xD;
               -  Fecal incontinence&#xD;
&#xD;
         11. Prior hemibody external radiotherapy, or systemic therapy with radionuclides (e.g.,&#xD;
             strontium-89, samarium-153, rhenium-186, or rhenium-188, or radium-223 dichloride).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Klotz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Canadian Urology Research Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

